Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis

被引：3

作者：

Hatanaka, Takeshi ^{[1
]}

Kakizaki, Satoru ^{[2
,3
]}

Hiraoka, Atsushi ^{[4
]}

Tada, Toshifumi ^{[5
]}

Hirooka, Masashi ^{[6
]}

Kariyama, Kazuya ^{[7
]}

Tani, Joji ^{[8
]}

Atsukawa, Masanori ^{[9
]}

Takaguchi, Koichi ^{[10
]}

Itobayashi, Ei ^{[11
]}

Fukunishi, Shinya ^{[12
]}

Tsuji, Kunihiko ^{[13
]}

Ishikawa, Toru ^{[14
]}

Tajiri, Kazuto ^{[15
]}

Ochi, Hironori ^{[16
]}

Yasuda, Satoshi ^{[17
]}

Toyoda, Hidenori ^{[17
]}

Ogawa, Chikara ^{[18
]}

Nishimura, Takashi ^{[19
]}

Shimada, Noritomo ^{[20
]}

Kawata, Kazuhito ^{[21
]}

Kosaka, Hisashi ^{[22
]}

Naganuma, Atsushi ^{[23
]}

Yata, Yutaka ^{[24
]}

Tanaka, Takaaki ^{[4
]}

Ohama, Hideko ^{[4
]}

Tada, Fujimasa ^{[4
]}

Nouso, Kazuhiro ^{[7
]}

Morishita, Asahiro ^{[8
]}

Tsutsui, Akemi ^{[10
]}

Nagano, Takuya ^{[10
]}

Itokawa, Norio ^{[9
]}

Okubo, Tomomi ^{[9
]}

Arai, Taeang ^{[9
]}

Imai, Michitaka ^{[14
]}

Koizumi, Yohei ^{[6
]}

Nakamura, Shinichiro ^{[5
]}

Kaibori, Masaki ^{[22
]}

Iijima, Hiroko ^{[19
]}

Hiasa, Yoichi ^{[6
]}

Kumada, Takashi ^{[25
]}

机构：

[1] Gunma Saiseikai Maebashi Hosp, Dept Gastroenterol, Maebashi, Japan

[2] Natl Hosp Org, Dept Clin Res, Takasaki Gen Med Ctr, Takasaki, Japan

[3] Gunma Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Maebashi, Japan

[4] Ehime Prefectural Cent Hosp, Gastroenterol Ctr, Matsuyama, Japan

[5] Japanese Red Cross Himeji Hosp, Dept Internal Med, Himeji, Japan

[6] Ehime Univ, Dept Gastroenterol & Metabol, Grad Sch Med, Matsuyama, Japan

[7] Okayama City Hosp, Dept Gastroenterol, Okayama, Japan

[8] Kagawa Univ, Dept Gastroenterol & Hepatol, Takamatsu, Japan

[9] Nippon Med Sch, Dept Internal Med, Div Gastroenterol & Hepatol, Tokyo, Japan

[10] Kagawa Prefectural Cent Hosp, Dept Hepatol, Takamatsu, Japan

[11] Asahi Gen Hosp, Dept Gastroenterol, Asahi, Japan

[12] Osaka Med & Pharmaceut Univ, Premier Dept Res Med, Osaka, Japan

[13] Teine Keijinkai Hosp, Ctr Gastroenterol, Sapporo, Japan

[14] Saiseikai Niigata Hosp, Dept Gastroenterol, Niigata, Japan

[15] Toyama Univ Hosp, Dept Gastroenterol, Toyama, Japan

[16] Matsuyama Red Cross Hosp, Ctr Liver Biliary Pancreat Dis, Matsuyama, Japan

[17] Ogaki Municipal Hosp, Dept Gastroenterol & Hepatol, Ogaki, Japan

[18] Japanese Red Cross Takamatsu Hosp, Dept Gastroenterol, Takamatsu, Japan

[19] Hyogo Med Univ, Dept Internal Med, Div Gastroenterol & Hepatol, Nishinomiya, Japan

[20] Otakanomori Hosp, Div Gastroenterol & Hepatol, Kashiwa, Japan

[21] Hamamatsu Univ, Dept Internal Med 2, Hepatol Div, Sch Med, Hamamatsu, Japan

[22] Kansai Med Univ, Dept Surg, Hirakata, Japan

[23] Natl Hosp Org, Dept Gastroenterol, Takasaki Gen Med Ctr, Takasaki, Japan

[24] Hanwa Mem Hosp, Dept Gastroenterol, Osaka, Japan

[25] Gifu Kyoritsu Univ, Dept Nursing, Ogaki, Japan

来源：

HEPATOLOGY RESEARCH | 2023年 / 53卷 / 08期

关键词：

antibiotic; atezolizumab; bevacizumab; gut microbiome; hepatocellular carcinoma; immune checkpoint inhibitor; proton pump inhibitor; MICROBIOME; EFFICACY; ALTER;

D O I：

10.1111/hepr.13905

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Aim: This retrospective study aimed to investigate the impact of proton pump inhibitor treatment (PPI) and antibiotic treatment on the therapeutic outcomes of hepatocellular carcinoma (HCC) patients receiving atezolizumab and bevacizumab (Atez/Bev). Methods: The present study included a total of 441 HCC patients who were treated with Atez/Bev in 20 Japanese institutions from September 2020 to April 2022. We adopted the inverse probability of treatment weight to adjust for imbalance in the baseline characteristics of patients with and without PPI treatment as well as patients with and without antibiotic treatment. Results: The progression-free survival (PFS) and overall survival (OS) of patients with and without PPI treatment did not differ to a statistically significant extent. In the weighted cohort, the difference in PFS and OS between the patients with and without PPI did not reach statistical significance (median PFS, 7.0 vs. 6.5 months, p = 0.07; 1-year survival rate 66.3% and 73.8%, p = 0.9). The PFS and OS in patients with antibiotic treatment were worse in comparison to patients without antibiotic treatment (median PFS, 3.8 vs. 7.0 months, p = 0.007; 1-year survival rate 58.8% and 70.3%, p = 0.01). In the weighted cohort, the PFS and OS of the two groups did not differ to a statistically significant extent (median PFS, 3.8 vs. 6.7 months, p = 0.2; 1-year survival rate, 61.8% and 71.0%, p = 0.6). Conclusions: The therapeutic outcomes of Atez/Bev in HCC patients did not differ between patients with and without PPI treatment or between patients with and without antibiotic treatment.

引用

页码：737 / 748

页数：12

共 50 条

[41] Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study
Kai, Machiko
Hikita, Hayato
Kazuki, Maesaka
Tahata, Yuki
Shinkai, Kazuma
Doi, Akira
Ohkawa, Kazuyoshi
Miyazaki, Masanori
Ishida, Hisashi
Matsumoto, Kengo
Nozaki, Yasutoshi
Yakushijin, Takayuki
Sakamori, Ryotaro
Kaneko, Akira
Iio, Sadaharu
Nawa, Takatoshi
Kakita, Naruyasu
Morishita, Naoki
Hiramatsu, Naoki
Usui, Takeo
Imanaka, Kazuho
Doi, Yoshinori
Sakakibara, Mitsuru
Yoshida, Yuichi
Oze, Tsugiko
Kodama, Takahiro
Tatsumi, Tomohide
Takehara, Tetsuo
PLOS ONE, 2024, 19 (01):
[42] Anti-PD-1 Autoantibody Predicts Survival of Patients With Hepatocellular Carcinoma Receiving Atezolizumab/ Bevacizumab
Sasaki, Yuki
Matsumoto, Kazuyuki
Takaki, Akinobu
Adachi, Takuya
Takahara, Masahiro
Ozato, Keita
Takeuchi, Yasuto
Sue, Masahiko
Miyake, Nozomi
Wada, Nozomu
Onishi, Hideki
Shiraha, Hidenori
Oda, Takashi
Tsutsumi, Koichiro
Nouso, Kazuhiro
Kariyama, Kazuya
Hagihara, Hiroaki
Moriya, Akio
Otsuka, Motoyuki
GASTRO HEP ADVANCES, 2024, 3 (08): : 1138 - 1147
[43] T-Cell Dynamics Predicts Prognosis of Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab
Lee, Hye Won
Park, Suebin
Park, Hye Jung
Cho, Kyung Joo
Kim, Do Young
Hwang, Byungjin
Park, Jun Yong
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (20)
[44] Association of proton pump inhibitor use with survival and adverse effects outcomes in patients with multiple myeloma: pooled analysis of three clinical trials
Almansour, Sara A.
Alqudah, Mohammad A. Y.
Abuhelwa, Ziad
Al-Shamsi, Humaid O.
Semreen, Mohammad H.
Bustanji, Yasser
Soare, Nelson C.
McKinnon, Ross A.
Sorich, Michael J.
Hopkins, Ashley M.
Abuhelwa, Ahmad Y.
SCIENTIFIC REPORTS, 2024, 14 (01)
[45] CLINICAL FACTORS ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA: A MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY
Maesaka, Kazuki
Hikita, Hayato
Kai, Machiko
Tahata, Yuki
Shinkai, Kazuma
Doi, Akira
Ohkawa, Kazuyoshi
Miyazaki, Masanori
Ishida, Hisashi
Matsumoto, Kengo
Nozaki, Yasutoshi
Yakushijin, Takayuki
Sakamori, Ryotaro
Kodama, Takahiro
Tatsumi, Tomohide
Takehara, Tetsuo
HEPATOLOGY, 2023, 78 : S1813 - S1813
[46] Association of proton pump inhibitor use with survival and adverse effects outcomes in patients with multiple myeloma: pooled analysis of three clinical trials
Sara A. Almansour
Mohammad A. Y. Alqudah
Ziad Abuhelwa
Humaid O. Al-Shamsi
Mohammad H. Semreen
Yasser Bustanji
Nelson C. Soare
Ross A. McKinnon
Michael J. Sorich
Ashley M. Hopkins
Ahmad Y. Abuhelwa
Scientific Reports, 14
[47] Outcomes of patients with unresectable hepatocellular carcinoma who developed an infection while receiving atezolizumab
Esmail, A.
Xu, J.
Burns, E.
Gee, K.
Wiechmann, C.
Zhang, Y.
Kieser, R.
Gong, Z.
Umoru, G.
Shah, S.
Sun, K.
Heyne, K.
Abdelrahim, M.
ANNALS OF ONCOLOGY, 2023, 34 : S156 - S156
[48] Risk of bleeding and thromboembolic events with atezolizumab/bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter, retrospective study
Ben Khaled, Najib
Moeller, Marie
Jochheim, Leonie
Leyh, Catherine
Ehmer, Ursula
Boettcher, Katrin
Leicht, Hans Benno
Rau, Monika
Sinner, Friedrich
Venerito, Marino
Gairing, Simon Johannes
Foerster, Friedrich
de Toni, Enrico
Geier, Andreas
Reiter, Florian P.
JOURNAL OF HEPATOLOGY, 2023, 78 : S51 - S51
[49] Response prediction model of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: multicenter retrospective study
Ueno, Masaki
Kosaka, Hisashi
Iida, Hiroya
Ida, Yoshiyuki
Aoi, Kazunori
Mori, Haruki
Miyamoto, Atsushi
Nishida, Yuko
Hayami, Shinya
Kawai, Manabu
Kaibori, Masaki
ONCOLOGY, 2023, 101 (09) : 565 - 574
[50] Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study
Yoo, Changhoon
Kim, Jwa Hoon
Ryu, Min-Hee
Park, Sook Ryun
Lee, Danbi
Kim, Kang Mo
Shim, Ju Hyun
Lim, Young-Suk
Lee, Han Chu
Lee, Joycelyn
Tai, David
Chan, Stephen Lam
Ryoo, Baek-Yeol
LIVER CANCER, 2021, 10 (02) : 107 - 114

← 1 2 3 4 5 →